Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology

Neurobiology of Disease

Volumn 36, Issue 1, 2009, Pages 96-102

  Drolet, Robert E ^a   Cannon, Jason R ^a   Montero, Laura ^a   Greenamyre, J Timothy ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha synuclein; Enteric nervous system; Gastrointestinal; Motility; Myenteric plexus; Parkinson's disease; Rotenone

Indexed keywords

ALPHA SYNUCLEIN; ROTENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; EXPOSURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; IMMUNOREACTIVITY; INTESTINE INNERVATION; LEWY BODY; MALE; MYENTERIC PLEXUS; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RAT;

ALPHA-SYNUCLEIN; ANIMALS; BODY WEIGHT; CELL DEATH; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; FORMIC ACIDS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; INSECTICIDES; MALE; NEURONS; PARKINSON DISEASE; RATS; RATS, INBRED LEW; ROTENONE; STATISTICS, NONPARAMETRIC;

EID: 69749124032     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.06.017     Document Type: Article

References (43)

1. Abbott R.D., et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57 (2001) 456-462
2. Anderson G., et al. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. Exp. Neurol. 207 (2007) 4-12
3. Beach T.G., et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol. 116 (2008) 277-288
4. Betarbet R., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
5. Bonifati V., et al. Unraveling the pathogenesis of Parkinson's disease-the contribution of monogenic forms. Cell. Mol. Life Sci. 61 (2004) 1729-1750
6. Braak H., and Del Tredici K. Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 70 (2008) 1916-1925
7. Braak H., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003) 197-211
8. Braak H., et al. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 110 (2003) 517-536
9. Braak H., et al. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 396 (2006) 67-72
10. Cannon J.R., et al. A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 34 (2009) 279-290
11. Cersosimo M.G., and Benarroch E.E. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov. Disord. 23 (2008) 1065-1075
12. Chaumette T., et al. Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterol. Motil. 21 (2009) 215-222
13. de Souza R.R., et al. Age-induced nerve cell loss in the myenteric plexus of the small intestine in man. Gerontology 39 (1993) 183-188
14. Greenamyre J.T., et al. Quantitative autoradiography of dihydrorotenone binding to complex I of the electron transport chain. J. Neurochem. 59 (1992) 746-749
15. Greene J.G., et al. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Exp. Neurol. (2009)
16. Hald A., and Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Exp. Neurol. 193 (2005) 279-290
17. Hawkes C.H., et al. Parkinson's disease: a dual-hit hypothesis. Neuropathol. Appl. Neurobiol. 33 (2007) 599-614
18. Hirsch E.C. Mechanism and consequences of nerve cell death in Parkinson's disease. J. Neural Transm. Suppl. 56 (1999) 127-137
19. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2003) S26-S36 discussion S36-S8
20. Lebouvier T., et al. Pathological lesions in colonic biopsies during Parkinson's disease. Gut 57 (2008) 1741-1743
21. Li Z.S., et al. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J. Neurosci. 26 (2006) 2798-2807
22. Mastroberardino P.G., et al. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol. Dis. 34 (2009) 417-431
23. Murphy E.M., et al. Quantification of subclasses of human colonic myenteric neurons by immunoreactivity to Hu, choline acetyltransferase and nitric oxide synthase. Neurogastroenterol. Motil. 19 (2007) 126-134
24. Natale G., et al. Parkinson's disease and the gut: a well known clinical association in need of an effective cure and explanation. Neurogastroenterol. Motil. 20 (2008) 741-749
25. Onyango I.G. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Neurochem. Res. 33 (2008) 589-597
26. Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease. Clin. Neurosci. 5 (1998) 136-146
27. Phillips R.J., and Powley T.L. As the gut ages: timetables for aging of innervation vary by organ in the Fischer 344 rat. J. Comp. Neurol. 434 (2001) 358-377
28. Poewe W. Non-motor symptoms in Parkinson's disease. Eur. J. Neurol. 15 Suppl. 1 (2008) 14-20
29. Schapira A.H. Oxidative stress in Parkinson's disease. Neuropathol. Appl. Neurobiol. 21 (1995) 3-9
30. Schapira A.H. Mitochondrial dysfunction in neurodegenerative disorders. Biochim. Biophys. Acta 1366 (1998) 225-233
31. Sherer T.B., et al. Environment, mitochondria, and Parkinson's disease. Neuroscientist 8 (2002) 192-197
32. Sherer T.B., et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22 (2002) 7006-7015
33. Sherer T.B., et al. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179 (2003) 9-16
34. Singaram C., et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 346 (1995) 861-864
35. Smalley W., et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 284 (2000) 3036-3039
36. Spillantini M.G., et al. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
37. Thompson C.A. Novartis suspends tegaserod sales at FDA's request. Am. J. Health Syst. Pharm. 64 (2007) 1020
38. Tian Y.M., et al. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease. Neuroscience 153 (2008) 634-644
39. Wakabayashi K., et al. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol. 79 (1990) 581-583
40. Wakabayashi K., et al. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol. 76 (1988) 217-221
41. Wang L., et al. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. NeuroReport 19 (2008) 873-876
42. Wysowski D.K., et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am. J. Gastroenterol. 96 (2001) 1698-1703
43. Zhang Y., et al. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol. Dis. 7 (2000) 240-250